Baljit Kaur

This paper identifies DELC2, a brain-penetrant CHI3L1 inhibitor, which reduces neuroinflammation and amyloid-β levels in Alzheimer's disease models.

This paper identifies and optimizes a molecular glue that stabilizes the NOS1AP-SCRIB interaction, showing therapeutic effects in Alzheimer's patient-derived neurons.

The paper optimizes a CHI3L1 inhibitor to improve pharmacokinetics and functional activity in 3D glioblastoma models, resulting in a more effective compound with better solubility and stability.

This paper optimizes a CHI3L1 inhibitor, G721-0282, to improve potency and drug-like properties, demonstrating functional efficacy in reversing astrocytic dysfunction in Alzheimer's disease.

This paper identifies a small molecule TREM2 modulator, EN020, that enhances microglial phagocytosis better than a known agonist.

This paper identifies a small molecule inhibitor of CHI3L1, DEL-C1, which modulates neuroinflammation in Alzheimer's disease through multiple validated mechanisms.

This study identifies a CHI3L1 inhibitor, compound 9e, through structure-based virtual screening of a large chemical space, showing efficacy in a 3D GBM model.

This paper identifies Z17 as a selective CHI3L1 inhibitor that restores astrocytic function and mitigates neuroinflammation in Alzheimer's disease.

HTS-Oracle uses AI to prioritize small molecule hits for challenging immune targets, reducing screening needs and increasing hit rates significantly.

This study identifies two small molecule CHI3L1 inhibitors using virtual screening and validates their activity in glioblastoma spheroids.

This paper uses affinity selection-mass spectrometry to identify small molecule binders of CHI3L1, finding one compound with moderate affinity that validates the approach for targeting this protein.

This paper identifies G28 as a potent CHI3L1 inhibitor through virtual screening, validates its binding affinity, and shows its efficacy in reducing GBM spheroid growth.